Current Care Therapy Selection for RA Relies on Trial-and-Error

Rheumatoid arthritis (RA) affects roughly 1.6 million people in the US and as much as 1% of the population worldwide.1 This chronic autoimmune disease attacks the lining of the joints on both sides of the body causing inflammation and pain. It can also lead to permanent joint damage as well as other complications in the eyes, mouth, and cardiovascular system. While remission is possible within 3 months with early treatment, the process of diagnosis and starting a b/tsDMARD can often take almost 2 years.2,3

A typical patient journey with RA can look like this:

Taking a closer look at this timeline we see that diagnosis of RA itself can take up to 8.5 months from the onset of symptoms.2

Additionally, once a patient is diagnosed and they are finally able to start treatment, a csDMARD such as methotrexate is most commonly the first treatment prescribed. Many, however, will have an inadequate response after 3-6 months without sufficient improvement to their disease and end up looking to add a b/tsDMARD for further relief and disease management.

Unfortunately, with over 20 different drug treatment options to choose from, selection of the right b/tsDMARD for each RA patient does not have a clear path and becomes a journey of trial-and-error.

Without clear direction from clinical guidelines on therapy selection, up to 90% of patients with RA are treated with TNFi therapies as a first-line biologic.4,5 According to a publication by Dr. Jeffrey Curtis, only about 1/3 of patients with RA achieve an ACR50 response at 6 months with a biologic after failing methotrexate.6  

All the while the disease continues to progress causing more pain and discomfort and increasing additional risk factors.

This now becomes a race against time for many patients which can lead to poor outcomes. Patients with RA with uncontrolled disease activity experience:

At Scipher Medicine®, we believe there is a better way to treat these patients and have developed the  PrismRA® test to improve upon this trial-and-error process. The PrismRA test is a precision medicine test that looks at 23 biologic features to predict inadequate response to TNFi therapy in adult patients with RA. With the addition of PrismRA to the care pathway, our goal is to help guide treatment selection for RA to help find the right medication for each patient sooner, getting them back to their lives and avoiding poor outcomes.13

To learn more about how we developed PrismRA read about our research and development process